10,425 Shares in Bio-Rad Laboratories, Inc. $BIO Purchased by Magnetar Financial LLC

Magnetar Financial LLC acquired a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 10,425 shares of the medical research company’s stock, valued at approximately $2,923,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Royal Bank of Canada lifted its position in Bio-Rad Laboratories by 25.2% during the first quarter. Royal Bank of Canada now owns 30,310 shares of the medical research company’s stock worth $7,382,000 after buying an additional 6,100 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Bio-Rad Laboratories by 45.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company’s stock valued at $25,575,000 after buying an additional 32,874 shares in the last quarter. Empowered Funds LLC increased its stake in shares of Bio-Rad Laboratories by 14.8% in the 1st quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company’s stock worth $377,000 after acquiring an additional 199 shares during the last quarter. Jane Street Group LLC increased its stake in shares of Bio-Rad Laboratories by 95.3% in the 1st quarter. Jane Street Group LLC now owns 37,383 shares of the medical research company’s stock worth $9,105,000 after acquiring an additional 18,239 shares during the last quarter. Finally, KBC Group NV raised its holdings in shares of Bio-Rad Laboratories by 12.7% during the 2nd quarter. KBC Group NV now owns 1,462 shares of the medical research company’s stock worth $353,000 after acquiring an additional 165 shares during the period. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories Stock Up 0.8%

Shares of BIO opened at $269.95 on Thursday. The firm has a market cap of $7.29 billion, a P/E ratio of 9.67 and a beta of 1.18. Bio-Rad Laboratories, Inc. has a 12-month low of $211.43 and a 12-month high of $343.12. The company’s 50-day moving average price is $293.75 and its 200 day moving average price is $300.72. The company has a current ratio of 5.62, a quick ratio of 4.19 and a debt-to-equity ratio of 0.16.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, February 12th. The medical research company reported $2.51 EPS for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.06). Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. The company had revenue of $693.20 million during the quarter, compared to analyst estimates of $694.64 million. During the same period in the previous year, the company earned $2.90 EPS. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. On average, sell-side analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Monday, December 29th. Wall Street Zen downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $358.50.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.